Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
There has been no report on whether the patients with colorectal cancer who are also inactive
Hepatitis B Carriers should receive Prophylactic Use or preemptive Use of an Anti-viral Drug
Entecavir. This open, randomized controlled clinical trial aims to compare the impact of the
prophylactic use or preemptive use of an anti-viral drug Entecavir on the outcomes of
patients with colorectal cancer who are also inactive hepatitis B carriers during
chemotherapy and the subsequent follow-ups.